搜索
 >  其他蛋白>CD20 >CD0-H52H3

Human CD20 / MS4A1 Full Length Protein, His Tag (HEK293)

分子别名(Synonym)

MS4A1,CD20,MS4A-1

表达区间及表达系统(Source)

Human CD20 Full Length, His Tag, HEK293 (CD0-H52H3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

Predicted N-terminus: Met 1

蛋白结构(Molecular Characterization)

Online(Met 1 - Pro 297) P11836-1

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 35.2 kDa. The protein migrates as 40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Delivered as bulk protein in a 0.2 μm filtered solution of 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH 7.5 with glycerol as protectant.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied as sterile liquid solution and shipped frozen with dry ice.

存储(Storage)

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. The product MUST be stored at -70°C or lower upon receipt;
  2. -70°C for 3 months under sterile conditions.
 

电泳(SDS-PAGE)

Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) SDS-PAGE gel

Human CD20 Full Length, His Tag, HEK293 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2-16 ng/mL (in presence of DDM and CHS) (QC tested).

Protocol

Biotinylated Human SPR

Immobilized Ofatumumab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 1-20 ng/mL (in presence of DDM and CHS) (QC tested).

Protocol

活性(Bioactivity)-SPR

Biotinylated Human SPR

MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 1.77 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Protocol

Biotinylated Human SPR

Ofatumumab (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 3.57 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

Biotinylated Human BLI

Loaded MabThera® (Rituximab) on ProteinA Biosensor, can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 8.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

背景(Background)

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

 

前沿进展

货号/价格

CD0-H52H3-20ug / ¥7800

CD0-H52H3-100ug / ¥29000

CD0-H52H3-500ug / ¥66000

开发建议
文档
联系电话:
400-682-2521(全国)
010-57737274(北京)
021-26136428(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
techsupport@acrobiosystems.com
CD20靶点信息
英文全称:B-lymphocyte antigen CD20
中文全称:B淋巴细胞抗原CD20
种类:Homo sapiens
上市药物数量:21详情
临床药物数量:93详情
最高研发阶段:批准上市
查看更多信息

消息提示

请输入您的联系方式,再点击提交!

确定